Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Zuberitamab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Zuberitamab is an antibody medicine for diffuse large B-cell lymphoma (DLBCL), the most common fast-growing type of non-Hodgkin lymphoma. It was developed in China by Zhejiang BioRay Biopharmaceutical and is sold there as 安瑞昔® (Anruixi®). It is given as a drip together with CHOP chemotherapy.
China's National Medical Products Administration (NMPA) approved it in May 2023 for adults with:
It is a prescription blood cancer medicine and should only be used under a haematologist or medical oncologist.
Most B-cell lymphoma cells carry a marker on their surface called CD20. Zuberitamab is a chimeric (part human, part mouse) monoclonal antibody that sticks to CD20. Once attached, it flags the cancer cell so the immune system can destroy it. BioRay describes it as China's first home-grown innovative anti-CD20 antibody, rather than a copy of an existing one.
The phase 3 trial, published in the Journal for ImmunoTherapy of Cancer in 2024, included 487 adults with newly diagnosed CD20-positive DLBCL. Two out of three received zuberitamab plus CHOP and the rest received a standard comparison antibody plus CHOP, for six cycles.
The Chinese prescribing information says zuberitamab must not be used on its own; it is always combined with standard CHOP chemotherapy:
It comes as a 100 mg in 10 mL vial of solution. The dose depends on height and weight, so the number of vials differs from person to person; for example, a body surface area of 1.6 m² needs 600 mg, or six vials. Your haematologist sets the exact plan.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Infusion reactions: reactions during or soon after the drip were the main difference from the comparison treatment (32.1% vs 19.9%). They were mostly chills (20.8%), fever (16.5%) and a rise in blood pressure (5.2%), usually within 1 to 2 hours of the first infusion. Almost all were mild or moderate; 1.5% of patients had a grade 3 reaction. The drip is given in hospital so the team can slow or pause it if needed.
Overall: side effect rates were similar between the two groups. 13.5% of patients on zuberitamab stopped the trial because of side effects, compared with 17.9% in the comparison group. Full Chinese prescribing information was not available to us, so ask your specialist about pregnancy, breastfeeding and other individual risks.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China (approval number 国药准字S20230028, May 2023). It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For lymphoma that comes back after first treatment, see our pages on Monjuvi and Zynlonta.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is stored and shipped exactly as directed on the pack, using temperature-controlled shipping where the pack requires it. Because the dose is worked out from body surface area, we confirm the number of vials for each cycle before ordering. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid specialist's prescription.
Large cancer hospitals here treat lymphoma patients from across North India, and dispatch from New Delhi keeps delivery times short.
Vials can be delivered to the hospital pharmacy ahead of each three-weekly CHOP cycle.
Oncologists in Bangalore can request the medicine for a named patient and receive a written quote before any order is placed.
A major referral centre for lymphoma care in South India, with hospitals used to handling imported cancer medicines.
We time each shipment around the patient's planned cycle date so treatment is not held up.
Patients in Kolkata and the eastern states can use the same documented import route.
The treating oncologist can share the pathology report and prescription with us to start the process.
We coordinate delivery to the treating hospital and keep the family updated at each step.
Patients treated at hospitals in Vellore can have each cycle's vials delivered directly to the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating centre.
We arrange supply to public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive the medicine at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
